Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue 3, 2011, Pages 234-236

  Borentain, P ^a,b   Gregoire, E ^a   Hardwigsen, J ^a   Garcia, S ^c   Durieux, O ^d   Le Treut, Y P ^a   Gerolami R ^a,b  

^a HÔPITAL DE LA CONCEPTION   (France)

^b University of the Mediterranean Aix Marseille II   (France)

^c HÔPITAL NORD   (France)

^d TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE; SORAFENIB;

ARTICLE; CASE REPORT; FATALITY; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVER TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; FATAL OUTCOME; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MIDDLE AGED; PYRIDINES;

MLCS; MLOWN;

EID: 80052306518     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2010.12.007     Document Type: Article

References (8)

1. Vitale, A., Volk, M.L., Pastorelli, D., Lonardi, S., Farinati, F., Burra, P., et al. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology 51 (2010), 165–173.
2. Boige, V., Barbare, J.C., Rosmorduc, O., Groupe de travail carcinome hépatocellulaire Prodige-Afef. Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations. Gastroenterol Clin Biol 32 (2008), 3–7.
3. Scappaticci, F.A., Fehrenbacher, L., Cartwright, T., Hainsworth, J.D., Heim, W., Berlin, J., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91 (2005), 173–180.
4. Margulis, V., Matin, S.F., Tannir, N., Tamboli, P., Swanson, D.A., Jonasch, E., et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 180 (2008), 94–98.
5. Moore, M., Hirte, H.W., Siu, L., Oza, A., Hotte, S.J., Petrenciuc, O., et al. Study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16 (2005), 1688–1694.
6. Akkouche, A., Sidéris, L., Leblanc, G., Leclerc, Y.E., Vafiadis, P., Dubé, P., Complications after colorectal anastomosis in a patient with metastatic rectal cancer treated with systemic chemotherapy and bevacizumab. Can J Surg 51 (2008), E52–E53.
7. Vibert, E., Azoulay, D., Hoti, E., Lacopinelli, S., Samuel, D., Salloum, C., et al. Progression of alphafoetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 10 (2010), 127–129.
8. Ebos, J.M., Lee, C.R., Cruz-Munoz, W., Bjarnason, G.A., Christensen, J.G., Kerbel, R.S., Accelerate metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15 (2009), 232–239.